Logo for Amniotics

Amniotics Investor Relations Material

Latest events

Logo for Amniotics

Q4 2023

22 Feb, 2024
Logo for Amniotics

Q3 2023

27 Nov, 2023
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies

Latest reports from Amniotics

Access all reports
Amniotics AB develops, manufactures, and sells stem cell therapies based on mesenchymal stem cells to treat severe life-threatening diseases. The company's lead drug candidate is PulmoStem for the treatment of inflammatory and fibrotic lung disease. It also develops CogniStem for the treatment of CNS indications; NephroStem for the treatment of kidney-specific indications; and CutiStem for the treatment of dermatological indications.